Ratchaphruek Hospital Public Company Limited (RPH.BK)
Khon Kaen, TH
Ratchaphruek Hospital Public Company Limited, known as Ratchaphruek Hospital, runs a healthcare facility in Thailand, delivering a comprehensive array of medical services. Its extensive offerings encompass various specialties, including internal medicine (such as dermatology, neurology, hematology, pulmonology, rheumatology, gastroenterology, nephrology, diabetes and endocrine care, and cardiology), a range of surgical procedures (general, urological, and colorectal), and specialized treatments in areas like pediatrics, orthopedics, ear-nose-throat (ENT), ophthalmology, obstetrics and gynecology, preventative health check-ups, dentistry, anesthesiology, emergency care, stroke management, breast health, hearing and balance, rehabilitation, and diagnostic radiology. The hospital also supplies medicines and medical provisions. Incorporated in 1993 in Khon Kaen, Thailand, the company was initially named Sithan Karnpat Company Limited, changing to its current designation in September 2016.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.41% | -2.01% | -3.37% | -1.21% | -1.61% | -7.05% | -19.34% | -4.31% | +1.67% | +1.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+3.3% Q1'26: -5.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+6.3% Q1'26: -31.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+12.3% Q1'26: +6.3% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+17.7% ★ Q1'26: +12.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+12.1% ★ Q1'26: +7.8% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-2.3% ★ Q1'26: -1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.01× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
409.80M
est: 410.50M (-0.2%)
|
413.02M
est: 412.00M (+0.2%)
|
532.89M
est: 528.00M (+0.9%)
|
816.58M
est: 813.00M (+0.4%)
|
799.33M
est: 786.00M (+1.7%)
|
1.41B
est: 1.19B (+18.5%)
|
1.33B
est: 1.26B (+5.5%)
|
1.16B
est: 1.02B (+13.9%)
|
1.13B
est: 1.06B (+6.1%)
|
1.16B
est: 1.23B (-5.5%)
|
| EBITDA |
102.00M
est: 129.99M (-21.5%)
|
92.91M
est: 130.47M (-28.8%)
|
104.58M
est: 167.20M (-37.5%)
|
217.06M
est: 257.46M (-15.7%)
|
213.49M
est: 248.91M (-14.2%)
|
599.02M
est: 377.47M (+58.7%)
|
457.67M
est: 398.06M (+15.0%)
|
326.00M
est: 322.69M (+1.0%)
|
299.54M
est: 331.06M (-9.5%)
|
285.09M
est: 384.16M (-25.8%)
|
| EBIT |
87.40M
est: 97.40M (-10.3%)
|
80.19M
est: 97.76M (-18.0%)
|
64.56M
est: 125.28M (-48.5%)
|
130.32M
est: 192.91M (-32.4%)
|
124.32M
est: 186.50M (-33.3%)
|
509.76M
est: 282.84M (+80.2%)
|
363.75M
est: 298.26M (+22.0%)
|
235.49M
est: 241.79M (-2.6%)
|
216.94M
est: 256.09M (-15.3%)
|
205.80M
est: 297.16M (-30.7%)
|
| Net Income |
67.90M
est: 98.27M (-30.9%)
|
63.04M
est: 60.06M (+5.0%)
|
48.43M
est: 54.60M (-11.3%)
|
96.41M
est: 92.81M (+3.9%)
|
93.84M
est: 72.23M (+29.9%)
|
402.99M
est: 259.90M (+55.1%)
|
286.47M
est: 294.82M (-2.8%)
|
184.45M
est: 114.65M (+60.9%)
|
172.53M
est: 117.32M (+47.1%)
|
182.37M
|
| SGA |
55.32M
est: 58.26M (-5.0%)
|
61.08M
est: 58.47M (+4.5%)
|
91.84M
est: 74.93M (+22.6%)
|
128.36M
est: 115.38M (+11.2%)
|
121.58M
est: 111.55M (+9.0%)
|
167.72M
est: 169.17M (-0.9%)
|
149.50M
est: 178.39M (-16.2%)
|
191.46M
est: 144.62M (+32.4%)
|
181.22M
est: 147.84M (+22.6%)
|
162.54M
est: 171.55M (-5.3%)
|
| EPS |
0.12
est: 0.18 (-33.3%)
|
0.12
est: 0.11 (+9.1%)
|
0.09
est: 0.10 (-11.3%)
|
0.18
est: 0.17 (+5.9%)
|
0.17
est: 0.13 (+28.5%)
|
0.74
est: 0.48 (+55.4%)
|
0.52
est: 0.54 (-3.7%)
|
0.34
est: 0.21 (+61.9%)
|
0.32
est: 0.22 (+45.5%)
|
0.34
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sudhon Sriyapant | Chairman of the Board & President | 428.4K | male |
| Teerawat Srinakarin | Chief Executive Officer & Director | 417.0K | — |
| Julalak Boonrith | Head of Internal Audit | — | female |
| Sireethorn Palkird | Chief Nursing Officer | — | female |
| Supaporn Sukhee | Chief of Accounting & Finance | — | female |
| Wadcharapron Wiboon | Chief Human Resources Officer & Human Resource Director | — | female |
| Associate Jiraporn Srinakarin | Chief Medical Officer | — | — |
| Weerada Thongtranon | Chief Information Officer | — | — |
| Chularat Sirisingh | Company Secretary & Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RPH.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
